Emerging Markets At Stake As Viehbacher Departs Sanofi?
This article was originally published in PharmAsia News
Executive Summary
As emerging markets represent 32% of Sanofi’s overall sales, the highest among big pharma firms, will the sudden departure of Viehbacher leave a dent in one of the firm’s key growth platforms?
You may also be interested in...
Sanofi Board Forces CEO Chris Viehbacher to Resign Amid Lantus Woes
Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.
China Biotech Hopes Innovation Wins The Day As Legislative Attacks In US Congress Increase
The latest development shows that BIOSECURE Act is gaining momentum in the US Congress and off Capitol Hill. In the meanwhile, the Chinese biotech sector embraces uncertainty but hopes that common interests in health innovation will prevail in the end.
US Senate Advances BIOSECURE Legislation As China Biotech Security Heats Up
The US Senate moves closer to new legislation that would restrict Chinese "biotech companies of concern” from operating in the US, potentially causing broad and far-reaching impact.